Objective response on nirogacestat improved from 34.3% at year one to 45.7% with continuous treatment for up to four years in the Phase 3 DeFi study, adding three complete and three partial responses versus the primary analysis. Median best tumor reduction deepened from −32.3% at year one to −75.8% among patients who completed at least four years. Patient-reported gains in pain, function, and quality of life were sustained through roughly 45 months. The incidence and severity of common adverse events declined after the first year, and the median treatment duration reached 33.6 months at the December 2024 final data cut.
The core development is a formal publication in the Journal of Clinical Oncology of DeFi’s long-term efficacy and safety, following the previously reported primary analysis that met PFS, ORR, and PRO endpoints in a randomized, double-blind, placebo-controlled design (142 patients; 1:1). Nirogacestat is approved in the U.S. and EU for adults with progressing desmoid tumors requiring systemic therapy. The new analysis focuses on patients randomized to active treatment and followed to the final cut, showing additional late responses, deeper shrinkage over time, and a safety profile that trended more manageable in later treatment years, with diarrhea, ovarian toxicity, rash, nausea, fatigue, and stomatitis remaining the most frequent events.
Strategically, the publication is a durability play that shores up the chronic-treatment narrative underpinning adoption, guideline placement, and payer positioning. Desmoid tumors can fluctuate, and the field has lacked clarity on optimal treatment duration. Demonstrating continued response accrual and deepening tumor control beyond year one supports long-term dosing, which strengthens the product’s economic and competitive moat as rival gamma secretase inhibitors and Wnt-pathway agents advance. The signal also arrives as HTA bodies and payers scrutinize rare-disease therapies for sustained benefit and clear continuation criteria. One caveat is survivor bias: the most dramatic tumor reductions are reported in a smaller subset that remained on treatment for four years, which stakeholders will weigh against intent-to-treat outcomes and real-world persistence.
For sites, the data validate multi-year management models: routine monitoring, dose modifications, and adherence support beyond the typical trial horizon. Safety operations must remain vigilant for ovarian toxicity, hepatic enzyme elevations, electrolyte shifts, and cutaneous events, with particular implications for women of reproductive age, where fertility counseling and monitoring protocols are operationally material. Sponsors and CROs running future desmoid studies will feel pressure to incorporate longer follow-up, rigorous PRO collection, and predefined stopping or de-escalation rules to address duration questions proactively. Regulators have already accepted PFS and PRO gains; this dataset may inform label discussions on duration and reinforce consensus guideline moves toward systemic therapy as first-line in appropriate cases. Payers will mine these data for continuation thresholds and may push for response-guided tapering or treatment holidays, given the chronic exposure implied by the median duration.
Next, watch for real-world evidence on discontinuation, retreatment after response, and fertility outcomes to translate these findings into practical algorithms. Head-to-head or sequencing data versus TKIs or other GSIs would clarify positioning, as would biomarker or imaging-based criteria for early de-escalation without compromising control. On the market access side, expect renewed HTA reassessments and outcomes-based contracting discussions tied to long-term benefit. The risk profile appears manageable and attenuates over time, but longer surveillance for dermatologic and hepatic signals remains a regulatory and pharmacovigilance priority. The unresolved question is not whether nirogacestat works over time, but how long patients should stay on therapy to balance depth of response, quality of life, reproductive health, and cost. This execution challenge will define uptake and competitiveness over the next cycle.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
